Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on June 5)
- Haemonetics Corporation HAE
- Athersys, Inc. ATHX
- BIO-TECHNE Corp TECH
- CareDx Inc CDNA
- Champions Oncology Inc CSBR
- CONMED Corporation CNMD
- Deciphera Pharmaceuticals Inc DCPH
- Inogen Inc INGN
- Intuitive Surgical, Inc. ISRG
- Ligand Pharmaceuticals Inc. LGND
- Madrigal Pharmaceuticals Inc MDGL
- MEI Pharma Inc MEIP
- Mesa Laboratories, Inc. MLAB
- Oncolytics Biotech, Inc. (USA) ONCY
- Xencor Inc XNCR
Down In The Dumps
(Stocks hitting 52-week lows on June 5)
- DENTSPLY SIRONA Inc XRAY
- Puma Biotechnology Inc PBYI
- TrovaGene TROV
Stocks In Focus
Vascular Biogenics Reports Positive Data On Platform
Vascular Biogenics Ltd VBLT presented data on its novel MOSPD2 program in oncology and inflammation at the 2018 BIO International Convention, which showed that MOSPD2 plays a key role in the regulation of cell motility.
"We continue to advance our exciting VB-600 series of antibodies as drug candidates for oncology and inflammatory indications," the company said.
The company is developing the VB-600 platform of biologic drug candidates for oncology and inflammation, with an IND filing expected by year-end 2019.
The stock jumped 44.19 percent to $3.10 in after-hours trading Tuesday.
Related Link: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Immunogen, Madrigal Announce Common Stock Offering
ImmunoGen, Inc. IMGN said it intends to offer 12 million shares in an underwritten common stock offering, with the entire shares being sold by the company.
The stock fell 4.27 percent to $10.98 in after-hours trading.
Separately, Madrigal announced the commencement of a common stock offering of $200 million of its common stock.
Madrigal lost 1.77 percent to $5.33 in after-hours trading.
Axovant Licenses Parkinson's disease Gene Therapy Candidate
Axovant Sciences Ltd AXON announced it has licensed the exclusive worldwide rights to develop and commercialize investigational gene therapy for Parkinson's disease OXB-102 – now renamed as AXO-Lenti-PD from Oxford BioMedica. Axovant said it plans to initiate a Phase 1/2 dose escalation study by the end of 2018.
The terms of the licensing deal calls for Axovant paying Oxford BioMedica $30 million in cash, potential milestone payments in excess of $812 million and tiered royalty on net sales, if AXO-Lenti-PD is approved.
The company also announced the appointment of Fraser Wright, an industry veteran, as the CTO for gene therapy programs.
EXACT Sciences Identifies Biomarker For Diagnosing Liver Cancer
EXACT Sciences Corporation EXAS and Mayo Clinic have developed a panel of blood-based DNA biomarkers, which would help in detecting hepatocellular carcinoma, according to a presentation made at the Digestive Disease Week.
The stock was up 4.95 percent to $65.55 in after-hours trading.
Akcea Announces Addition to Board
Akcea Therapeutics Inc AKCA said Richard Moscicki, who had a tenure in the FDA as well as pharma companies, has been appointed to its board.
The stock rose 3.26 percent to $23.79 in after-hours trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
